The association of cardiovascular comorbidities with malignant and benign colorectal neoplasms
6 affiliations
- 1Department of Family and Osteopathic Medicine, Texas College of Osteopathic Medicine, University of North Texas Health Sciences Center, Fort Worth, Texas, United States of America.
- 2Medical Student, Texas College of Osteopathic Medicine, University of North Texas Health Sciences Center, Fort Worth, Texas, United States of America.
- 3Medical Director of Nuclear and Echovascular Imaging, Northeast Georgia Medical Center, Assistant Professor of Medicine, Augusta University, Gainesville, Georgia, United States of America.
- 4Resident Physician, Texas Health Harris Methodist, Fort Worth, Texas, United States of America.
- 5Department of Internal Medicine, Guthrie Robert Packet Hospital, Sayre, Pennsylvania, United States of America.
- 6Department of Internal Medicine, Texas College of Osteopathic Medicine, University of North Texas Health Sciences Center, Fort Worth, Texas, United States of America.
Abstract
Background: Each year, thousands of patients are diagnosed with gastrointestinal (GI) bleeding. Many of these patients undergo colonoscopy and are subsequently diagnosed with benign or malignant colorectal neoplasms. The aim of this study is to evaluate whether patients with cardiovascular comorbidities, many of whom are on anti-platelet or anticoagulation therapy, are more likely to be diagnosed with new benign or malignant colorectal neoplasms than patients without cardiovascular comorbidities. Methods: From the 2007–2011 NIS, 802,080 primary lower GI bleed admissions (ICD-9) were identified; 283,925 had cardiovascular comorbidities. We compared patients with vs without these comorbidities for the primary outcome of new benign or malignant colorectal neoplasms. Weighted analyses accounting for the complex survey design were performed in SAS 9.4, with trends assessed using Cochran–Armitage tests and linear regression and associations with colorectal cancer stage evaluated by multinomial logistic regression (p ≤ 0.05). Results: Between 2007–2011, the odds of malignant colorectal neoplasms increased between 49.9% and 65.3% for patients without cardiovascular comorbidities when presenting with a lower GI bleed, compared to those with cardiovascular comorbidities. Between 2007 and 2011, the most notable and statistically significant difference was observed in 2010, when patients with cardiovascular comorbidities had 10.5% higher odds of being diagnosed with benign colorectal neoplasms than those without cardiovascular comorbidities. Conclusion: Patients presenting with a lower gastrointestinal bleed without cardiovascular comorbidities were significantly more likely to be diagnosed with malignant colorectal neoplasms than those with cardiovascular comorbidities.
Related
- Persistent Malignant Stem Cells Drive Relapse After Transplantation in the Myelodysplastic Neoplasms
- FBXO17 regulates the malignant progression of colorectal cancer via the Wnt/β-catenin pathway
- Systemic inflammation response index and total cholesterol in relation to the occurrence of major adverse cardiovascular and cerebrovascular events in patients with myeloproliferative neoplasms.
- Occurrence and Severity of Mental Health Disorders Among Patients Treated for Malignant Neoplasms: A Narrative Review with Preliminary Quantitative Synthesis.
- Acquired TRAIL Resistance Promotes Cancer Stemness and Malignant Behavior through CD44-SPHK1-STAT3 Signaling in Colorectal Cancer
BibTeX
@article{wani2026association,
title = {{The association of cardiovascular comorbidities with malignant and benign colorectal neoplasms}},
author = {Farah Wani and Ivan Magallanes Marrufo and Vedang Bhavsar and Rebecca Whitmer and Jagmeet Singh and Asim Kichloo},
journal = {PLOS One},
year = {2026},
month = oct,
doi = {10.1371/journal.pone.0356302},
url = {https://doi.org/10.1371/journal.pone.0356302},
note = {CC BY},
}
RIS
TY - JOUR
TI - The association of cardiovascular comorbidities with malignant and benign colorectal neoplasms
AU - Farah Wani
AU - Ivan Magallanes Marrufo
AU - Vedang Bhavsar
AU - Rebecca Whitmer
AU - Jagmeet Singh
AU - Asim Kichloo
PY - 2026
DA - 2026/10/21
JO - PLOS One
DO - 10.1371/journal.pone.0356302
UR - https://doi.org/10.1371/journal.pone.0356302
AB - Background: Each year, thousands of patients are diagnosed with gastrointestinal (GI) bleeding. Many of these patients undergo colonoscopy and are subsequently diagnosed with benign or malignant colorectal neoplasms. The aim of this study is to evaluate whether patients with cardiovascular comorbidities, many of whom are on anti-platelet or anticoagulation therapy, are more likely to be diagnosed with new benign or malignant colorectal neoplasms than patients without cardiovascular comorbidities. Methods: From the 2007–2011 NIS, 802,080 primary lower GI bleed admissions (ICD-9) were identified; 283,925 had cardiovascular comorbidities. We compared patients with vs without these comorbidities for the primary outcome of new benign or malignant colorectal neoplasms. Weighted analyses accounting for the complex survey design were performed in SAS 9.4, with trends assessed using Cochran–Armitage tests and linear regression and associations with colorectal cancer stage evaluated by multinomial logistic regression (p ≤ 0.05). Results: Between 2007–2011, the odds of malignant colorectal neoplasms increased between 49.9% and 65.3% for patients without cardiovascular comorbidities when presenting with a lower GI bleed, compared to those with cardiovascular comorbidities. Between 2007 and 2011, the most notable and statistically significant difference was observed in 2010, when patients with cardiovascular comorbidities had 10.5% higher odds of being diagnosed with benign colorectal neoplasms than those without cardiovascular comorbidities. Conclusion: Patients presenting with a lower gastrointestinal bleed without cardiovascular comorbidities were significantly more likely to be diagnosed with malignant colorectal neoplasms than those with cardiovascular comorbidities.
SN - 1932-6203
ER -